Evaluation of the Real-World Effectiveness of Vaccines against COVID-19 at a Local Level: Protocol for a Test-Negative Case-Control Study.
COVID-19 vaccines
case–control studies
district hospitals
effectiveness
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
received:
09
04
2022
revised:
15
05
2022
accepted:
19
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Vaccines against COVID-19 approved for use in the EU/EEA have been shown to be highly effective against wild-type SARS-CoV-2. However, their effectiveness against new variants may be reduced. This study aims to evaluate the effectiveness of vaccines against COVID-19 in the prevention of symptomatic and severe disease, during pre- and post-omicron phases. Individuals who sought treatment at the emergency department of a Portuguese hospital with COVID-19-like disease and were tested for SARS-CoV-2 are the subjects of the study. Patients who received a positive result are considered cases, while those with negative results are the controls. The test-negative case-control method is one of the study designs recommended by WHO to estimate the effectiveness of vaccines against COVID-19. The main advantage of this design is that it controls for the healthcare seeking bias, commonly present in traditional cohort and case-control designs. This study may have broad implications for understanding the real-world performance of the COVID-19 vaccines at the local level, which may play a key role in promoting adherence to vaccination. Moreover, this study may contribute to inform decisions regarding booster doses and variant-specific vaccine formulations leading to the control of this and future pandemics.
Identifiants
pubmed: 35632578
pii: vaccines10050822
doi: 10.3390/vaccines10050822
pmc: PMC9147572
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Environ Res Public Health. 2020 Aug 13;17(16):
pubmed: 32823775
PLoS One. 2012;7(8):e41785
pubmed: 22870248
Clin Pract. 2021 Oct 21;11(4):778-784
pubmed: 34698149
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
BMJ. 2021 Aug 20;374:n1943
pubmed: 34417165
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296676
Emerg Infect Dis. 2022 Feb;28(2):331-337
pubmed: 34876242
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
J Med Virol. 2022 May;94(5):2269-2274
pubmed: 34978339
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194
Inflammopharmacology. 2021 Aug;29(4):1075-1090
pubmed: 34241782
Vaccine. 2013 Nov 19;31(48):5634-42
pubmed: 23856332
Euro Surveill. 2013 Jan 31;18(5):
pubmed: 23399422
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Influenza Other Respir Viruses. 2013 Sep;7(5):729-37
pubmed: 23078073
Euro Surveill. 2009 Nov 05;14(44):
pubmed: 19941774
BMJ. 2021 Aug 20;374:n2015
pubmed: 34417194
CMAJ. 2021 May 17;193(20):E723-E734
pubmed: 33906966
Infect Dis Poverty. 2021 Nov 14;10(1):132
pubmed: 34776011
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Am J Epidemiol. 1991 Feb 15;133(4):323-31
pubmed: 1899778
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Nat Med. 2021 Dec;27(12):2136-2143
pubmed: 34728831